These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11983265)

  • 1. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.
    Gruters RA; van Baalen CA; Osterhaus AD
    Vaccine; 2002 May; 20(15):2011-5. PubMed ID: 11983265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.
    Calarota SA; Kjerrström A; Islam KB; Wahren B
    Hum Gene Ther; 2001 Sep; 12(13):1623-37. PubMed ID: 11535166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals.
    Addo MM; Altfeld M; Rosenberg ES; Eldridge RL; Philips MN; Habeeb K; Khatri A; Brander C; Robbins GK; Mazzara GP; Goulder PJ; Walker BD;
    Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1781-6. PubMed ID: 11172028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation in rhesus macaques of Tat and rev-targeted immunization as a preventive vaccine against mucosal challenge with SHIV-BX08.
    Verrier B; Le Grand R; Ataman-Onal Y; Terrat C; Guillon C; Durand PY; Hurtrel B; Aubertin AM; Sutter G; Erfle V; Girard M
    DNA Cell Biol; 2002 Sep; 21(9):653-8. PubMed ID: 12396607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.
    van Baalen CA; Pontesilli O; Huisman RC; Geretti AM; Klein MR; de Wolf F; Miedema F; Gruters RA; Osterhaus AD
    J Gen Virol; 1997 Aug; 78 ( Pt 8)():1913-8. PubMed ID: 9266987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.
    van Baalen CA; Guillon C; van Baalen M; Verschuren EJ; Boers PH; Osterhaus AD; Gruters RA
    Eur J Immunol; 2002 Sep; 32(9):2644-52. PubMed ID: 12207349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV/AIDS. HLA leaves its footprints on HIV.
    McMichael A; Klenerman P
    Science; 2002 May; 296(5572):1410-1. PubMed ID: 12029119
    [No Abstract]   [Full Text] [Related]  

  • 8. Cytotoxic T lymphocyte recognition of HLA-B*5101-restricted HIV-1 Rev epitope which is naturally processed in HIV-1-infected cells.
    Tomiyama H; Chujoh Y; Shioda T; Miwa K; Oka S; Kaneko Y; Takiguchi M
    AIDS; 1999 May; 13(7):861-3. PubMed ID: 10357388
    [No Abstract]   [Full Text] [Related]  

  • 9. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
    Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
    J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
    Yang OO
    Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
    [No Abstract]   [Full Text] [Related]  

  • 11. Helper and cytotoxic T cell responses of HIV type 1-infected individuals to synthetic peptides of HIV type 1 Rev.
    Blazevic V; Ranki A; Krohn KJ
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1335-42. PubMed ID: 8573390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTL responses to regulatory proteins Tat and Rev in HIV-1 B'/C virus-infected individuals.
    Jia MM; Hong KX; Chen JP; Liu HW; Liu S; Zhang XQ; Zhao HJ; Shao YM
    Biomed Environ Sci; 2008 Aug; 21(4):314-8. PubMed ID: 18837295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes.
    Hinkula J; Svanholm C; Schwartz S; Lundholm P; Brytting M; Engström G; Benthin R; Glaser H; Sutter G; Kohleisen B; Erfle V; Okuda K; Wigzell H; Wahren B
    J Virol; 1997 Jul; 71(7):5528-39. PubMed ID: 9188627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants.
    Fischer W; Perkins S; Theiler J; Bhattacharya T; Yusim K; Funkhouser R; Kuiken C; Haynes B; Letvin NL; Walker BD; Hahn BH; Korber BT
    Nat Med; 2007 Jan; 13(1):100-6. PubMed ID: 17187074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The rationale behind a vaccine based on multiple HIV antigens.
    Rollman E; Bråve A; Boberg A; Gudmundsdotter L; Engström G; Isaguliants M; Ljungberg K; Lundgren B; Blomberg P; Hinkula J; Hejdeman B; Sandström E; Liu M; Wahren B
    Microbes Infect; 2005 Nov; 7(14):1414-23. PubMed ID: 16257558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia.
    Allen TM; O'Connor DH; Jing P; Dzuris JL; Mothé BR; Vogel TU; Dunphy E; Liebl ME; Emerson C; Wilson N; Kunstman KJ; Wang X; Allison DB; Hughes AL; Desrosiers RC; Altman JD; Wolinsky SM; Sette A; Watkins DI
    Nature; 2000 Sep; 407(6802):386-90. PubMed ID: 11014195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with Rev and Tat against AIDS.
    Osterhaus AD; van Baalen CA; Gruters RA; Schutten M; Siebelink CH; Hulskotte EG; Tijhaar EJ; Randall RE; van Amerongen G; Fleuchaus A; Erfle V; Sutter G
    Vaccine; 1999 Jun; 17(20-21):2713-4. PubMed ID: 10418922
    [No Abstract]   [Full Text] [Related]  

  • 18. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization.
    Ramakrishna L; Anand KK; Mohankumar KM; Ranga U
    J Virol; 2004 Sep; 78(17):9174-89. PubMed ID: 15308713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for CTL-mediated selection of Tat and Rev mutants after the onset of the asymptomatic period during HIV type 1 infection.
    Guillon C; Stankovic K; Ataman-Onal Y; Biron F; Verrier B
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1283-92. PubMed ID: 17209772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
    Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
    J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.